Study links obesity and diabetes to higher recurrence rates in liver cancer

Hepatocellular carcinoma, a type of liver cancer associated with hepatitis infections, is known to have a high recurrence rate after cancer removal. Recent advances in antiviral therapy have reduced the number of patients affected, but obesity and diabetes are factors in hepatocellular carcinoma prevalence. However, these factors' effects on patient survival and cancer recurrence have been unclear.

To gain insights, Dr. Hiroji Shinkawa's research team at Osaka Metropolitan University's Graduate School of Medicine analyzed the relationship between diabetes mellitus, obesity, and postoperative outcomes in 1,644 patients with hepatocellular carcinoma who underwent liver resection.

The results revealed that the risk of recurrence after two years postoperatively was approximately 1.5 times higher in the case of comorbid obesity and 1.3 times higher in the case of diabetes mellitus. In addition, the risk of recurrence after five years postoperatively was 3.8 times higher in the case of comorbid obesity and 2 times higher in the case of comorbid diabetes alone.

This study is expected to contribute to the early detection of cancer recurrence and the design of appropriate treatment strategies. Because the risk of late recurrence is higher in hepatocellular carcinoma with comorbid obesity and diabetes, controlling obesity and diabetes is an important treatment strategy for hepatocellular carcinoma."

Dr. Hiroji Shinkawa, Osaka Metropolitan University's Graduate School of Medicine

The findings were published in Liver Cancer.

Source:
Journal reference:

Shinkawa, H. (2024). Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study. Liver Cancer. doi.org/10.1159/000540858.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer